Utomilumab

BIOLOGICAL14 trials

Sponsors

Pfizer, M.D. Anderson Cancer Center, George W. Sledge Jr., Adrienne G. Waks, City of Hope Medical Center

Conditions

Advanced CancerAdvanced MalignanciesAdvanced Malignant Solid NeoplasmBreast CancerCOL6A3 PositiveCastration-Resistant Prostate CarcinomaDiffuse Large B-Cell LymphomaFollicular Lymphoma

Phase 1

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

TerminatedNCT02554812

PfizerAdvanced Cancer

Start: 2015-11-09End: 2023-03-23Updated: 2024-07-30

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Active, not recruitingNCT03217747

M.D. Anderson Cancer CenterAdvanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm +7

Start: 2017-08-02End: 2026-04-30Updated: 2025-10-23

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

CompletedNCT03290937

M.D. Anderson Cancer CenterMetastatic Colorectal Carcinoma, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8 +2

Start: 2017-12-27End: 2025-12-30Updated: 2026-01-06

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

CompletedNCT03318900

M.D. Anderson Cancer CenterCOL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive +1

Start: 2018-09-04End: 2023-12-20Updated: 2024-11-07

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

CompletedNCT03364348

George W. Sledge Jr.HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer +4

Start: 2017-10-30End: 2022-02-14Updated: 2022-10-19

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

CompletedNCT03440567

City of Hope Medical CenterRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma +2

Start: 2018-04-02End: 2024-06-26Updated: 2025-03-26

Rituximab + Immunotherapy in Follicular Lymphoma

TerminatedNCT03636503

Dana-Farber Cancer InstituteFollicular Lymphoma

Start: 2018-10-30End: 2023-07-30Updated: 2025-02-06

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

TerminatedNCT03704298

Kite, A Gilead CompanyRelapsed/Refractory Large B-cell Lymphoma

Start: 2018-11-20End: 2022-12-15Updated: 2024-06-28

Phase 2

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

TerminatedNCT03258008

M.D. Anderson Cancer CenterMalignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer

Start: 2018-04-04End: 2021-11-05Updated: 2022-12-16

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Active, not recruitingNCT03414658

Adrienne G. WaksBreast Cancer

Start: 2018-06-21End: 2026-05-31Updated: 2025-07-02

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

RecruitingNCT03971409

Laura Huppert, MD, BAInvasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer +6

Start: 2019-07-08End: 2026-06-30Target: 150Updated: 2025-05-02

Phase 3

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

TerminatedNCT02951156

PfizerDiffuse Large B-Cell Lymphoma

Start: 2016-12-16End: 2019-12-02Updated: 2020-12-17

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruitingNCT05059522

PfizerAdvanced Malignancies, NSCLC, Ovarian Cancer +2

Start: 2021-09-29End: 2026-09-30Updated: 2025-06-25

Unknown Phase

A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS

PfizerGESELECTEERDE LOKAAL GEVORDERDE OF GEMETASTASEERDE CARCINOMEN SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS

Target: 50Updated: 2024-02-28

Related Papers

A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies

The Oncologist2025-03-011 citations

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

Therapeutic Advances in Medical Oncology2025-01-0110 citations

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.

2024-05-1612 citations

Abstract RF02-06: AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658)

Cancer Research2024-05-02

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Journal of Immunotherapy and Precision Oncology2023-11-249 citations

584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

Regular and Young Investigator Award Abstracts2023-10-31

A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.

2023-10-185 citations

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2022-10-0152 citations

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.

2021-10-2310 citations

8 Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist

Regular and Young Investigator Award Abstracts2020-11-011 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

2017-10-23590 citations

Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Journal of Clinical Oncology2017-05-204 citations

Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study.

Journal of Clinical Oncology2016-05-208 citations